At the same time that the United Kingdom’s Standards Agency announced plans to establish a legal pathway for CBD in food and dietary supplements (recommending a reasonable upper limit of 70mg/day of CBD for healthy adults), the US FDA continues to tread water – even missing a congressionally-requested deadline last week to deliver a report on its enforcement policies.
Why the delay? Why is FDA acting our against CBD in the first place? And what can be done about it?
In Episode 2 of the US Hemp Roundtable’s new podcast, Hemp Table Talk, two of the nation’s leading experts on FDA’s treatment of CBD have a detailed conversation about where we are and where we may be going. The Roundtable’s General Counsel, Jonathan Miller, and our FDA counsel, Rend Al-Mondhiry both dig deep into the issue, while explaining the complex situation for a layperson audience. Additionally, Jonathan interviews Jon Vaught of Front Range Biosciences, who testified at the FDA’s public hearing, about the impact of the agency’s inaction on the industry and hemp farmers.
Click here to listen in.
Take Action In Your State
Make Your Voice Heard
Track the latest hemp and CBD legislative developments in all 50 states and contact your elected representatives to demand action.Go to the State Action Center